TK 216

Drug Profile

TK 216

Alternative Names: TK-216

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Tokalas, Inc.
  • Developer Oncternal Therapeutics, Inc.
  • Class Antineoplastics
  • Mechanism of Action Proto-oncogene-protein-c-ets inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ewing's sarcoma
  • Research Acute myeloid leukaemia; Diffuse large B cell lymphoma

Most Recent Events

  • 06 Dec 2016 Early research in Acute myeloid leukaemia in USA (unspecified route)
  • 06 Dec 2016 Early research in Diffuse large B cell lymphoma in USA (unspecified route)
  • 06 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia and Diffuse large B cell lymphoma presented at the 58th Annual Meeting of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top